The Association of the British Pharmaceutical Industry (ABPI) have responded to the publication of a consultation today by the National Institute for Health and Care Excellence (NICE) and NHS England on evaluating and funding drugs and other health technologies.
Billed as "Patients to get faster access to the most cost effective treatments under proposed changes to NICE's process" by NICE and NHS England, in response, Mike Thompson, CEO of the ABPI said:
“Today’s consultation sets out a number of proposals which have a significant impact on how new medicines will be brought to patients in the UK. We share the objectives set out by NICE and NHS England to: improve efficiency; manage affordability in the NHS; and ensure decisions are reached reliably on medicines for rare diseases. However, we think the thresholds and methodologies proposed in this consultation can be changed and improved.
We look forward to working with NICE and NHS England to ensure the thresholds are set at the right levels and in a way that maximises the speed with which NHS patients can get access to those medicines.
Medicines in the UK are already subject to rigorous value assessment by NICE and cost controls through a deal with the government that already caps NHS medicines spend. Any decision to implement further restrictions needs to be appropriate, in the best interest of patients and support investment in the medicines of the future."
ABPI Press Office
9am to 5pm Monday to Friday: +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441
5pm to 9am and weekends: +44 (0) 20 7747 1445
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.